| Identification | Back Directory | [Name]
SB242235 | [CAS]
193746-75-7 | [Synonyms]
CS-668
SB242235
SB242235 ≥95%
SB-242235; SB242235
4-[4-(4-Fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxypyrimidine
4-(4-(4-Fluorophenyl)-1-(piperidin-4-yl)-1H-iMidazol-5-yl)-2-MethoxypyriMidine
Pyrimidine, 4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-2-methoxy- | [Molecular Formula]
C19H20FN5O | [MDL Number]
MFCD08690575 | [MOL File]
193746-75-7.mol | [Molecular Weight]
353.39 |
| Chemical Properties | Back Directory | [Boiling point ]
568.4±60.0 °C(Predicted) | [density ]
1.34 | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
DMF: 25 mg/ml; DMSO: 20 mg/ml; Ethanol: 30 mg/ml | [form ]
Powder | [pka]
9.91±0.10(Predicted) |
| Hazard Information | Back Directory | [Biological Activity]
SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 μM in human chondrocytes. | [in vitro]
SB 242235 (0-10 μM) dose-dependently inhibits the activation of MAPKAP K2 with an IC 50 of 1.0 μM in human chondrocytes stimulated with IL-1β.
SB 242235 inhibits intracellular p38 activity, MAPKAP K2 was then isolated from these cells and assayed using HSP27 as a substrate.
Western Blot Analysis | Cell Line: | Human chondrocytes | | Concentration: | 0 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM | | Incubation Time: | < td class="col2"> 15 minutes | Result: | Dose-dependently inhibited the activation of MAPKAP K2 with an IC 50 of 1.0 μM. | | [target]
IC50: 1.0 μM (p38 MAPK, primary human chondrocytes) | [storage]
Store at -20°C |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|